Журнал Современные проблемы науки и образования

2070-7428

Общество с ограниченной ответственностью "Издательский Дом "Академия Естествознания"

ART-23938

ОРГАНОПРОТЕКТИВНЫЕ СВОЙСТВА ОСНОВНЫХ ГРУПП САХАРОСНИЖАЮЩИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ

Евсина

М.Г.

Evsina

M.G.

evsinam@mail.ru

Вишнева

Е.М.

Vishneva

E.M.

e.m.vishneva@mail.ru

Чеписова

М.В.

Chepisova

M.V.

m.chepisova@mail.ru

Государственное бюджетное образовательное учреждение высшего профессионального образования «Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации, кафедра факультетской терапии и эндокринологии; Екатеринбург, Россия State Educational Institution of Higher Professional Education "The Ural State Medical University" Ministry of Health of the Russian Federation, Department fakultetstkoy therapy and endocrinology; Ekaterinburg, Russia Муниципальное автономное учреждение «Городская клиническая больница №14», Екатеринбург, Россия Municipal autonomous institution "City Clinical Hospital №14», Ekaterinburg, Russia

30 06 2015

6 306 306

This is an open-access article distributed under the terms of the CC BY 4.0 license.

https://science-education.ru/ru/article/view?id=23938

Сахарный диабет 2 типа (СД 2 типа) к настоящему времени является одной из наиболее частых причин смерти в современном обществе. Причиной является прогрессирование микрососудистых (диабетическая ретинопатия, нефропатия и нейропатия) и макрососудистых осложнений (патология коронарных, церебральных и периферических сосудов). Ведущей причиной развития всех сосудистых осложнений сахарного диабета является хроническая гипергликемия. Учитывая многокомпонентный характер поражения органов-мишеней при СД 2 типа, в его лечении на первый план выходит не только контроль углеводного обмена, но и органопротекция. В настоящем обзоре обсуждаются результаты локальных и масштабных клинических исследований, в которых имеются данные об оценке органопротективных свойств основных групп пероральных сахароснижающих препаратов, а также анализируются молекулярные механизмы этих эффектов.

Type 2 diabetes mellitus (T2DM) is one of the most frequent causes of death in modern society. The reasons are advanced microvascular (nephropathy, retinopathy) and macrovascular complications (coronary heart disease, peripheric atherosclerosis). The leading cause of all vascular complications of T2DM is a chronic hyperglycemia. Taking into account multicomponent character of target organs damages in diabetic patients treatment needs to be focused not only on control of hyperglycemia, but also on organs protection. In the following review, we will present results of local and large-scale clinical trials with data on organs protection properties of the main groups of hypoglycemic medication, and also molecular mechanisms of these effects will be analyzed.

сахарный диабет 2 типа органопротекция сахароснижающие лекарственные препараты

type 2 diabetes mellitus organs protection hypoglycemic medication

1. Дедов И.И., Шестакова М.В., Галстян Г.Р. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск) // Сахарный диабет. - 2015. - Т. 18, № 1. - С. 5.

2. Adamikova А. Possibilities of therapy GLP1 RA for diabetics with nephropathy / А. Adamikova // Vnitr Lek. – 2015. – Vol. 61, №4. – P. 312-315.

3. Alessi M.C., Juhan-Vague I. PAI-1 and the metabolic syndrome: the links, causes and consequences / M.C. Alessi, I. Juhan-Vague // Arterioscler Thromb Vasc Biol. – 2006. - Vol. 26, №10. – P. 2200–2207.

4. Andraws R., Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials) /R. Andraws, D.L. Brown // Am. J. Cardiol. – 2007. – Vol. 99. – Р. 1006–1012.

5. Baxter G.F. Role of adenosine in delayed preconditioning of myocardium / G.F. Baxter // Cardiovasc Re. - 2002. – Vol. 55. – Р. 483–494.

6. Buse J.B., Rosenstock J., Sesti G. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) // Lancet. – 2009. – Vol. 374. – P. 39–47.

7. Caballero A.E., Delgado A., Aguilar-Salinas C.A. et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial // J Clin Endocrinol Metab. – 2004. – Vol. 89, № 8. – Р. 3943–3948.

8. Calvert J.W., Gundewar S., Jha S. et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling // Diabetes. – 2008. - Vol. 57, № 3. - Р. 696–705.

9. Chakraborty A., Chowdhury S., Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients /A. Chakraborty, S. Chowdhury, M. Bhattacharyya// Diabetes Res Clin Pract. – 2011. - Vol. 93, № 1. - Р. 56–62.

10. Cox M.E., Rowell J., Corsino L. et al. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and effi cacy // Drug Healthcare Patient Saf. - 2010. - Vol. 2, № 7. —Р. 19.

11. Darsalia V., Ortsater H. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride /V. Darsalia, H. Ortsater// Diabetes. – 2013. - Vol. 62, № 4. – Р. 1289-1296.

12. Drucker D.J., Sherman S.I., Gorelick F.S. et al. Incretin-based therapies for the treatment of type 2 diabetes: Evaluation of the risks and benefits // Diabetes Care. – 2010. - Vol. 33. – Р. 428-433.

13. Fanghänel G., Silva U., Sanchez-Reyes L. et al. Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes // Rev Invest Clin. – 1998. - Vol. 50, № 5. Р. 389–394.

14. Gebel E. New SGLT-2 Meds Target the Kidneys / E. Gebel// Diabetes Forecast. – 2013. - Vol. 6. – Р.207-212.

15. Grant P.J. Beneficial effects of metformin on haemostasis and vascular function in man / P.J. Grant // Diabetes Metab. – 2003. - Vol. 29, № 4. – Р. 6544–6552.

16. Gregorio F., Ambrosi F., Manfrini S. et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin // Diabet Med. – 1999. - Vol. 16, № 12. – Р. 1016–1024.

17. Haffner S.M., Lehto S., Rönnemaa T. et al. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction // N Engl J Med. – 1998. - Vol. 339, № 4. - Р. 229–234.

18. Ji C., Xue G.F. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF /C. Ji, G. F. Xue // Brain Res. – 2015. – Vol. 10. – P.1016.

19. Katakam P.V., Ujhelyi M.R., Hoenig M. et al. Metformin improves vascular function in insulin-resistant rats // Hypertension. – 2000. – Vol. 35. - Р. 108–112.

20. Kim Y.W., Park S.Y., Kim J.Y. et al. Metformin restores the penile expression of nitric oxide synthase in high-fat-fed obese rats // J Androl. – 2007. - Vol. 28, № 4. - Р. 555–560.

21. Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment // Pharmacol Rev. – 2008. – Vol. 60. – P. 470–512.

22. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials // Lancet. – 2007. – Vol. 370. – P. 1129–1136.

23. Laube H. Acarbose. An update of its therapeutic use in diabetes treatment /H. Laube// Clin Drug Invest . – 2002. - Vol. 22. – P. 141–156.

24. Le D. C., Khodabandehlou T., Vimeux M. Impaired hemorheological properties in diabetic patients with lower limb arterial ischaemia // Clin Hemorheol Microcirc. - 2001. - Vol. 25, № 2. – Р. 43–48.

25. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients / T.M. Lee, T.F. Chou // J.Clin Endocrinol Metab. – 2003. – Vol. 88. - 531-537.

26. Lee T.I., Kao Y.H., Chen Y.C. et al. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes // Int J Cardiol. - 2013. - Vol. 168. – Р. 5390–5395.

27. Li L., Mamputu J.C., Wiernsperger N. et al. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin // Diabetes. - 2005. - Vol. 54. – Р.7.

28. Lim S.W., Jin L. Inhibition of dipeptidyl peptidase IV protects tacrolimus-induced kidney injury / S.W. Lim, L. Jin// Lab Invest. – 2015. - Vol. 95, №10. – Р.1174-1185.

29. Maeda S., Yamagishi S., Matsui T. et al. Beneficial effects of vildagliptin on retinal injury in obese type 2 diabetic rats // Ophthalmic Res. – 2013. – Vol. 50. – Р. 221–226.

30. Malaguarnera M., Giugno I., Ruello P., et al. Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridemias // Br J Clin Pharmac. – 1999. – Vol. 48. - №605–609.

31. Mamputu J.C., Wiernsperger N., Renier G. Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation // Br. J. Diabetes Vasc. Dis. – 2003. – Vol. 3, №4. – Р. 302 –310.

32. Mu J., Woods J., Zhou Y.P. et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes // Diabetes. — 2006. — № 55. — Р. 1695–1704.

33. Mudaliar S., Henry R.R., Boden G. et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin // Diabetes Technol. Ther. - 2014. -Vol. 16, № 3. - P. 137-144.

34. Muller S., Denet S., Candiloros H. et al. Action of metformin on erythrocyte membrane fluidity in vitro and in vivo // Eur J Pharmacol. – 1997. – Vol. 337, № 1. – Р.103–110.

35. Nauck M.A. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes /M.A. Nauck// Drug design, development and therapy. – 2014. - № 8. – Р. 1335–1380.

36. Nauck M.A., Del Prato S., Meier J.J. et al. Dapaglifl ozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial // Diabetes Care. – 2011. – Vol. 34, №9. – Р. 2015-2022.

37. Nissen S., Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes /S.Nissen, K.Wolski// Тhe NEW ENG. J. of MEDICINE. – 2007. - №356. – Р.24.

38. Pavlović D., Kocić R., Kocić G. et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes // Diabetes Obes Metab. – 2000. – Vol. 2, №4. – Р. 251–256.

39. PROactive: Pioglitazone Reduces Recurrent Stroke in Patients with Diabetes. – Medscape, 9/4/06.

40. Renner S., Blutke A. et al. Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models // J Pathol. – 2015. – Vol. 12. – Р. 1.

41. Rosenstock J., Baron M.A., Dejager S. et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial // Diabetes Care. – 2007. – Vol. 30. – Р. 217–223.

42. Sarwar N., Gao P., Seshasai S.R. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies // Lancet. – 2010. – Vol. 375, №9733. – Р. 2215–2222.

43. Scirica B.M., Bhatt D.L., Braunwald E. et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus // N Engl J Med. – 2013. – Vol. 369, №14. – Р.1317-1326.

44. Sobel B.E., Hardison R.M., Genuth S. et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial // Circulation. – 2011. – Vol. 124, № 6. – Р. 695–703.

45. Strojek K., Yoon K.H., Hruba V. et al. Eff ect of dapaglifl ozin in patients with type 2 diabetes who haveinadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial // Diabetes, Obesity and Metabolism. – 2011. – Vol. 13. – Р. 10.

46. The physiology and pharmacology of incretins in type 2 diabetes mellitus //Diabetes, Obesity and Metabolism. – 2008. – Vol. 10. – P.14-21.

47. Yaturu S., Bryant B., Jain S. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men // Diabetes Care. – 2007. – Р. 15.

48. Wiernsperger N.F., Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication /N.F. Wiernsperger, E. Bouskela// Diabetes Metab. – 2003. – Vol. 29. – Р. 6577–6587.

49. Wulffelé M.G., Kooy A., de Zeeuw D. et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review // J Intern Med. – 2004. – Vol. 256, №1. – Р. 1–14.